Milestones in pathology —from histology to molecular biology
SummaryAutopsy, histology and cytology have been and histology and cytology still are the main diagnostic tools in surgical pathology. During the last two decades molecular biology gradually has extended the diagnostic armamentarium. In tumor pathology molecular biology techniques are used to diagnose and subclassify tumors, predict response to therapies and identify therapeutic targets. Molecular pathology has evolved into a  novel focus of clinical pathology and transforms the historically morphology based discipline. Traditional pathology and molecular pathology combine and guide tumor therapy. (Source: Memo - Maga...
Source: Memo - Magazine of European Medical Oncology - January 9, 2017 Category: Cancer & Oncology Source Type: research

Distinct computed tomography features of non-small-cell lung cancer in a  European population with EML4-ALK translocation
SummaryBackgroundTreatment of advanced EML4-ALK-translocation-positive non-small-cell lung cancer (NSCLC) with an ALK tyrosine kinase inhibitor (TKI) is now standard of care. Since EML4-ALK gene fusion is rare in NSCLC and testing depletes both tissue samples and health care funds, deciding who to screen is critical. CT features associated with EML4-ALK-positive cases may help prioritize individual patients for ALK testing in settings where biopsy size or health care factors make ubiquitous testing difficult.MethodsWe used well-described computed tomography (CT) lung tumor features to distinguish EML4-ALK-translocation-pos...
Source: Memo - Magazine of European Medical Oncology - December 19, 2016 Category: Cancer & Oncology Source Type: research

A global congress digest on lung cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 14, 2016 Category: Cancer & Oncology Source Type: research

Short overview on the current treatment of chronic myeloid leukemia in chronic phase
SummaryThis short review on current treatment options in chronic myeloid leukemia (CML) in the chronic phase summarizes the latest version of the ELN treatment recommendations dating from 2013 and indicates treatment situations not yet reflected in these recommendations. Daily practice in CML management is complicated by the recently observed treatment-emergent vascular and pulmonary adverse events in second- or later-generation tyrosine kinase inhibitors (TKIs), the lack of guidance with respect to the best TKI for initial treatment, as well as the optimal TKI sequence because no prospective randomized comparative data fo...
Source: Memo - Magazine of European Medical Oncology - December 14, 2016 Category: Cancer & Oncology Source Type: research

ASCO update 2016: colorectal cancer
SummaryAt this year ’s annual meeting of the American Society of Clinical Oncology, held during 3–7 June 2016 in Chicago, USA, investigators discussed the latest findings in colorectal cancer research. The main topics were immune checkpoint inhibition therapy in colorectal cancer and the prognostic and predictive i nfluence of sidedness in the primary tumor location. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 7, 2016 Category: Cancer & Oncology Source Type: research

ASCO update 2016
SummaryThe past few years have seen major progress in cancer research and treatment. Today we are able to select treatments based on molecular profiling of tumors and do not solely rely on tumor type and stage. The most recent advance has taken place in the field of immunotherapy, and at this year ’s ASCO again a huge number of studies were reported dealing with immunotherapy. In Europe we expect approval of different immunotherapies in various entities ranging from head and neck cancer, urothelial cancer, gastric cancer to lung cancer and colorectal cancer. But immunotherapy is not the onl y area of progress. There ...
Source: Memo - Magazine of European Medical Oncology - December 7, 2016 Category: Cancer & Oncology Source Type: research

Post ASCO update 2016 —lung cancer
SummaryThe aim of this short review is to summarize the most important data relating to the field of thoracic tumors presented at the 2016 ASCO annual meeting. For small cell lung cancer (SCLC) the treatment algorithms once again remain unchanged. The CONVERT study was not able to show superiority of a modern chemoradiotherapy regimen using once daily fractionation over the historical standard of hyperfractionated chemoradiotherapy. With rovalpituzumab tesirine a promising new agent is in development, leading to encouraging treatment results in patients with pretreated, extensive SCLC disease on phase IB level. Regarding n...
Source: Memo - Magazine of European Medical Oncology - December 5, 2016 Category: Cancer & Oncology Source Type: research

Extravasation emergencies: state-of-the-art management and progress in clinical research
SummaryIn cancer treatment, extravasation is defined as an inadvertent instillation or leakage of cytotoxic drugs into the perivascular space during infusion. As a  dreaded complication of chemotherapy, extravasation has gained increasing attention in recent years. Classified according to their subcutaneous toxicity, three types of cytotoxins have been established: vesicants, irritants and nonvesicant drugs. Vesicant cytotoxic drugs may induce tissue damage, ulceration and tissue necrosis. Although we have established measures to manage extravasation emergencies, prevention is of paramount importance. This may be achi...
Source: Memo - Magazine of European Medical Oncology - December 5, 2016 Category: Cancer & Oncology Source Type: research

Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer
SummaryThe introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the therapy of non-small cell lung cancer (NSCLC) with activating mutations of the EGF receptor has opened a  new area of lung cancer treatment strategies and led to an enthusiastic search for additional genetic aberrations. Genetic drivers such asEML4-ALK (EML4: echinoderm microtubule-associated protein-like 4; ALK: anaplastic lymphoma kinase) and proto-oncogene tyrosine protein kinase transcribed from the ROS1-gene (ROS1) rearrangements have been detected and specific treatment options have been developed. A  ...
Source: Memo - Magazine of European Medical Oncology - November 30, 2016 Category: Cancer & Oncology Source Type: research

ASCO 2016: highlights in breast cancer
SummaryAt the 2016 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented. MA17.R was the first randomized phase  III trial to evaluate the prolongation of adjuvant aromatase-inhibitor (AI) therapy from 5 to 10 years; while a significant reduction of disease-free survival events was observed in the extended treatment group, the absolute difference was relatively small and longer endocrine therapy resulted i n a higher fracture rate. A combined analysis of three North American trials emphasized the superiority of anthracycline containing adjuvant chemotherapy reg...
Source: Memo - Magazine of European Medical Oncology - November 30, 2016 Category: Cancer & Oncology Source Type: research

Searching for the Achilles ’ heel of cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 30, 2016 Category: Cancer & Oncology Source Type: research

Molecular pathogenesis of chronic myelomonocytic leukemia
SummaryRecent insights into the pathophysiology of chronic myelomonocytic leukemia (CMML) have been obtained by the molecular and biological characterization of primary leukemic cells from patients and from animal models. Almost 3  decades ago extensive myeloid colony growth in semisolid cultures without exogenous growth factors was observed as an in vitro characteristic of a subgroup of CMML patients. Recent data suggest that this phenomenon was probably the first indication of an hyperactive RAS signaling pathway in these patients. Although the mutation landscape in CMML is heterogeneous and molecular aberratio...
Source: Memo - Magazine of European Medical Oncology - November 21, 2016 Category: Cancer & Oncology Source Type: research

Molecular pathogenesis of chronic myeloid leukemia
SummaryChronic myeloid leukemia (CML) is a  paradigm for effective targeted therapy and is characterized by the hallmarkBCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a  problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 10, 2016 Category: Cancer & Oncology Source Type: research

ASCO update: gastric cancer
SummaryTreatment of gastric cancer has improved substantially during the past decade. The aim of this short review is to highlight abstracts from this year ’s ASCO Annual Meeting and the ASCO GI Meeting. The CRITICS trial showed no significant difference in overall survival by the addition of postoperative radiochemotherapy in the curative setting. In the palliative setting, targeting claudin could be a very promising novel treatment approach as show n by the first results of the phase II FAST trial. Many small trials show interesting results of immune checkpoint inhibitors in gastric cancer. Predictive biomarkers, h...
Source: Memo - Magazine of European Medical Oncology - November 8, 2016 Category: Cancer & Oncology Source Type: research

DA-EPOCH-R: An alternative treatment for high-risk diffuse large B  cell lymphoma?
SummaryDiffuse large B  cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with an annual incidence of 7–8 cases per 100,000 per year. With standard induction therapy comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R/CHOP), 40% of all patients get cured. Patients re lapsing or being refractory to R/CHOP have a poor prognosis with a 10 % cure rate. On the other hand, the prognosis for patients with an event-free survival of 24 months is excellent. Despite the possibility of identifying patients at high risk for R/CHOP failure at the time o...
Source: Memo - Magazine of European Medical Oncology - October 28, 2016 Category: Cancer & Oncology Source Type: research

PD-L1 testing, fit for routine evaluation? From  a pathologist’s point of view
SummaryTumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1). Checkpoint inhibitors (ICI) provide encouraging therapeutic results in non-small cell lung cancers (NSCLC) and may soon be used in 2nd or 1st line therapy. Currently PD-L1 immunohistochemistry (IHC) expression assessed on tumour cells is used as a  predictive biomarker, since better patient outcomes are often, but not always associated with increased tumour cell PD-L1 IHC expression. However pre-analytical variables, different anti-PD-L1 clone...
Source: Memo - Magazine of European Medical Oncology - October 28, 2016 Category: Cancer & Oncology Source Type: research

Primary non-Hodgkin ’s lymphoma of the gingiva: a case report and review of the literature
We report the case of a 40-year-old woman who presented with a gingival mass that was diagnosed as diffuse large B‑cell lymphoma (DLBCL). The patient wa s treated with chemoradiotherapy, thus, achieving a complete remission, and the patient is currently free of disease. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 28, 2016 Category: Cancer & Oncology Source Type: research

Treatment of chronic myelomonocytic leukemia
SummarySince chronic myelomonocytic leukemia (CMML) has been classified within myelodysplastic syndromes (MDS) for a long time, most treatment data are derived from MDS trials. Owing to the limited number of CMML patients included in these trials, results are analyzed for the whole study population rather than for CMML patients as a distinct group. CMML patients with a myeloproliferative type of disease were often excluded. Therefore, generalization of data gained from MDS trials is very problematic. This review provides a brief overview of the treatment possibilities for patients with CMML. The paucity of existing clinica...
Source: Memo - Magazine of European Medical Oncology - October 25, 2016 Category: Cancer & Oncology Source Type: research

Soft tissue sarcomas & amp; GIST
SummarySoft tissue sarcomas (STS) are a  rare and heterogeneous disease sharing mesenchymal origin. While classification of different STS subtypes has generated insight into their molecular pathogenesis, treatment response, and prognosis, oncological management still poses major clinical challenges. Despite considerable evolution in defi nition of optimal treatment strategies over the past decade there is a critical need of new and less toxic therapeutic approaches for the treatment of metastatic sarcoma. This review covers the latest clinical study highlights for soft tissue sarcomas and gastroinestinal stromal ...
Source: Memo - Magazine of European Medical Oncology - October 18, 2016 Category: Cancer & Oncology Source Type: research

Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a  focus on the T790M-resistant mutation
SummaryThe molecular characterisation of nonsquamous lung cancer has now become a  standard procedure. In addition to the rare EML4-ALK and ROS-1 mutations, the detection of an epidermal growth factor receptor (EGFR) mutation has become a crucial factor in the selection of an optimal targeted therapy. Deletion of exon 19 and the L858R point mutation account for approximately 90  % of activating EGFR mutations and patients with these mutations are highly sensitive to treatment with EGFR tyrosine kinase inhibitors (EGFR TKIs). First-generation EGFR TKIs (gefitinib, erlotinib) reversibly inhibit the EGFR tyro...
Source: Memo - Magazine of European Medical Oncology - October 11, 2016 Category: Cancer & Oncology Source Type: research

Healthcare resource utilization and G ‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia
ConclusionsResults indicate considerable FN-related HCRU in all countries. Frequent lack of G ‑CSF primary prophylaxis was observed, particularly in Slovakia. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 19, 2016 Category: Cancer & Oncology Source Type: research

Focus on multiple myeloma at ASH 2015
SummaryMultiple myeloma was prominently featured during the American Society of Hematology 2015 meeting. Important presentations were related to standards of first-line therapy of myeloma, disease assessment, and treatment of relapsed disease. New innovative treatments for myeloma are emerging, which will likely open new therapeutic avenues in the near future. This review aims to give a  brief overview of the topic, focusing on presentations with relevance for clinical practice. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 19, 2016 Category: Cancer & Oncology Source Type: research

Novel strategies in the management of chronic lymphocytic leukemia (CLL)
SummaryThis review discusses promising new approaches in the management of chronic lymphocytic leukemia (CLL) that were recently presented at the annual meeting of the American Society of Hematology meeting in 2015. In total, 405 abstracts concerning biological and clinical aspects of CLL were presented. The review concentrates on clinical data regarding improved treatment strategies for treatment-na ïve patients as well as those with relapsed/refractory disease. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 19, 2016 Category: Cancer & Oncology Source Type: research

Antiangiogenic therapies in ovarian cancer
SummaryAngiogenesis plays a  pivotal role in normal ovarian physiology as well as in the formation and progression of ovarian cancer. Several well-designed phase II and III trials studied the efficacy of antiangiogenic agents in advanced ovarian cancer. The results of these trials demonstrated significa ntly prolonged progression-free survival when antiangiogenic agents were used as a maintenance therapy. To date, no effect on overall survival could be ascertained. The most widely studied antiangiogenic agent, bevacizumab – a monoclonal humanized antibody against vascul...
Source: Memo - Magazine of European Medical Oncology - September 15, 2016 Category: Cancer & Oncology Source Type: research

ASH 2015 —insights and outlooks
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 14, 2016 Category: Cancer & Oncology Source Type: research

Reversal of direct oral anticoagulants in hemophilia treatment
SummaryDuring the 57th annual meeting of the American Society of Hematology 2015 in Orlando, Florida, various aspects in the field of hemostaseology were presented. The Choosing Wisely ® campaign pointed out the importance of the critical use of diagnostic tools to rule out pulmonary embolism and questioned the relevance of thrombophilia testing in women undergoing routine infertility evaluation. Furthermore, the approval of idarucizumab, a specific antidote for the reversal of the anticoagulant effects of the direct thrombin inhibitor dabigatran, was highlighted. Finally, hemophilia specialists awaited the result...
Source: Memo - Magazine of European Medical Oncology - September 12, 2016 Category: Cancer & Oncology Source Type: research

A welcome statement from the associate Editor-in-Chief
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2016 Category: Cancer & Oncology Source Type: research

Welcome to the new associate Editor-in-Chief of memo
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 31, 2016 Category: Cancer & Oncology Source Type: research

Developments in neuro-oncology
SummaryA short statement on the most recent developments in the neuro-oncology field, including the new WHO Classification of Tumors of the Central Nervous System (2016) and current treatment strategies. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 30, 2016 Category: Cancer & Oncology Source Type: research

Rationale of an economically driven PD1 biomarker development in lung cancer —an academic dilemma
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 29, 2016 Category: Cancer & Oncology Source Type: research

ASH 2015 – stem cell transplantation
SummaryHematopoietic stem cell transplantation (HSCT) remains one of the most dynamic fields in hematology, as reflected by the large number of abstracts on new developments and establishing concepts in this scientific and clinical area, presented at the ASH meeting in December 2015. The role of haploidentical transplantation for recipients lacking an HLA-matched donor was further strengthened, and the use of an intelligently designed and carefully developed concept of immunomodulation, namely posttransplant cyclophosphamide, enabling successful transplantation across the multi-antigeneic HLA-barrier. Furthermore, with the...
Source: Memo - Magazine of European Medical Oncology - August 23, 2016 Category: Cancer & Oncology Source Type: research

Indolent lymphoma at ASH 2015: new treatment approaches
SummaryAt the last American society of hematology (ASH) meeting new genetic prognostic tools for follicular lymphoma (FL) were presented. Recent clinical data support the potential use of chemotherapy-free combinations in treatment-na ïve FL, but potential additive toxicities have to be considered. In relapsed disease the bcl2 inhibitor venetoclax (ABT-199) is very promising in combination with chemo-immunotherapy. Furthermore the concept of CAR-T cell therapy seems to be appropriate in highly refractory disease.In younger patients with mantle cell lymphoma (MCL) minimal residual disease (MRD) and positrone emission t...
Source: Memo - Magazine of European Medical Oncology - August 23, 2016 Category: Cancer & Oncology Source Type: research

ASCO Chicago 2016
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 4, 2016 Category: Cancer & Oncology Source Type: research

Acute myeloid leukemia: highlights from ASH 2015
Summary Despite of the progress achieved in recent years for acute myeloid leukemia (AML) treatment, there is still a  need for improvement, both for younger and elderly patients. This review covers studies for AML presented at the ASH 2015 annual meeting. The presentations selected offer a glimpse of the future of AML treatment. Also in AML insights into the molecular pathogenesis can be translated into clinical practice where a major step has been set with the first positive trial with respect to overall survival for the tyrosine kinase inhibitor midostaurin. Also for older patients, unfit for chemotherap...
Source: Memo - Magazine of European Medical Oncology - July 27, 2016 Category: Cancer & Oncology Source Type: research

Practice changing information in aggressive lymphoma, ASH 2015
Summary Out of the numerous papers dealing with lymphoma at the American Society of Hematology (ASH) 2015 meeting, three could change clinical practice. The DA-EPOCH-R regimen has improved the evidence for efficacy in Burkitt lymphoma. For lymphoproliferative disease after solid organ transplantation rituximab is a reasonable first-line treatment and nonresponders can be salvaged with R‑CHOP. For anaplastic large cell lymphoma the addition of etoposide to the CHOP regimen is an option. However, better regimens with new drugs are eagerly awaited. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 20, 2016 Category: Cancer & Oncology Source Type: research

Immunotherapy for head and neck squamous cell carcinoma
Summary Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being investigated in clinical phase III trials for head and neck squamous cell carcinoma (HNSCC). Data available from these trials indicate substantial activity accompanied by a favorable safety and toxicity profi...
Source: Memo - Magazine of European Medical Oncology - June 20, 2016 Category: Cancer & Oncology Source Type: research

CDK4/6 inhibition in luminal breast cancer
Summary Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are aimed to overcome endocrine resistance. The selective CDK4/6 inhibitor palbociclib has shown promising results in metastatic luminal breast cancer when used in combination with endocrine therapy both in the first-line setting as in pretreated women. The drug showed a manageable safety profile with uncomplic...
Source: Memo - Magazine of European Medical Oncology - June 20, 2016 Category: Cancer & Oncology Source Type: research

Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option
Summary Classic hairy cell leukemia (HCL) is a rare indolent B‑cell-lymphoproliferative disorder, first described as a distinct disease entity in 1958. After more than two decades without effective chemotherapeutic options and a dismal prognosis of less than 5 years, only the introduction of interferon‑α (IFN‑α) allowed for response rates between 80–90 % and survival improvement. Nowadays, however, patients are rarely treated with IFN-α as purine analogues were found to be highly effective in HCL facilitating a near normal life span in most cases. Moreo...
Source: Memo - Magazine of European Medical Oncology - June 17, 2016 Category: Cancer & Oncology Source Type: research

Immune checkpoint blockade in ovarian cancer
Summary Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years. Although some reports could evidence a successful induction of anti-tumour T‑cells, in general, these attempts did not translate into clinically significant activity. As has already been shown in other tumour entities, immune checkpoint blockade &nda...
Source: Memo - Magazine of European Medical Oncology - June 2, 2016 Category: Cancer & Oncology Source Type: research

Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?
Summary The incidence of prostate cancer is strongly correlated with age, with 35 % of patients aged 65–74 years and 25 % aged 75 years or older being affected [1]. Prostate cancer is third leading cause of cancer death among men aged 80 years and older. Of patients dying of prostate cancer, 41 % are aged 75–84 years, and 30 % above 85 years [2]. Fortunately treatment for metastatic castration-resistant prostate cancer (mCRPC) has evolved dramatically in the last few years. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 2, 2016 Category: Cancer & Oncology Source Type: research

Initial emergencies in children and adolescents with malignant hematologic –oncological diseases
Summary During the last few decades cure rates in children and adolescents with malignant diseases have approached 75 –80 %. While this has been mainly achieved by a reduction of relapses, nowadays, prevention of disease- and therapy-related deaths has come more and more into focus. Initial emergencies in pediatric hematology and oncology represent rare but life-threatening situations which can be recognized by the combination of a patient’s medical history, age, clinical symptoms, laboratory parameters, and imaging studies. In the present review, both disease- and therapy-related oncological emergencie...
Source: Memo - Magazine of European Medical Oncology - June 1, 2016 Category: Cancer & Oncology Source Type: research

Long-term treatment of hairy cell leukemia with interferon- α: still a viable therapeutic option
Summary Classic hairy cell leukemia (HCL) is a  rare indolent B‑cell-lymphoproliferative disorder, first described as a distinct disease entity in 1958. After more than two decades without effective chemotherapeutic options and a dismal prognosis of less than 5 years, only the introduction of interferon‑α (IFN‑α) allowed for response rates between 80–90 % and survival improvement. Nowadays, however, patients are rarely treated with IFN-α as purine analogues were found to be highly effective in HCL facilitating a near normal life span in most cases. Moreover, no...
Source: Memo - Magazine of European Medical Oncology - June 1, 2016 Category: Cancer & Oncology Source Type: research

Intravascular large B ‑cell lymphoma
We present a case who could be treated successfully with chemotherapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2016 Category: Cancer & Oncology Source Type: research

memo —new frontiers to be reached
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2016 Category: Cancer & Oncology Source Type: research

Endometrial cancer treated with levonorgestrel-releasing intrauterine device for almost three years in an elderly woman with comorbidity
Summary In this case report we describe the treatment of a 95-year-old woman with endometrioid adenocarcinoma. She suffered from cardiovascular comorbidity and did not want surgical treatment. Instead a levonorgestrel-releasing intrauterine device (Mirena) was inserted. She had progression of the tumor but with a minimum of symptoms and side effects. At the final examination there were no signs of extra uterine disease. The levonorgestrel-releasing intrauterine device may be an acceptable alternative to surgery in severely comorbid patients, or if the patient refuses surgical treatment. (Source: Mem...
Source: Memo - Magazine of European Medical Oncology - May 31, 2016 Category: Cancer & Oncology Source Type: research

Initial emergencies in children and adolescents with malignant hematologic–oncological diseases
Summary During the last few decades cure rates in children and adolescents with malignant diseases have approached 75–80 %. While this has been mainly achieved by a reduction of relapses, nowadays, prevention of disease- and therapy-related deaths has come more and more into focus. Initial emergencies in pediatric hematology and oncology represent rare but life-threatening situations which can be recognized by the combination of a patient’s medical history, age, clinical symptoms, laboratory parameters, and imaging studies. In the present review, both disease- and therapy-related oncological eme...
Source: Memo - Magazine of European Medical Oncology - May 20, 2016 Category: Cancer & Oncology Source Type: research

Circulating tumor cells and circulating tumor DNA in colon cancer
Abstract It is known that tumor cells have the ability to penetrate into the bloodstream. The identification of such circulating tumor cells (CTC) determines the prognosis in several tumors, including colon cancer. Tumor DNA (ctDNA), which is only a part of the total circulating DNA obtained from the blood of cancer patients, is also further separated from plasma. This separation of the neoplastic derivatives of the primary tumor and metastases (CTC, ctDNA, RNA, proteome) in plasma is called “liquid biopsy.” CTC increasingly represents the pool of tumor cells that can initiate the growth of metastatic ...
Source: Memo - Magazine of European Medical Oncology - May 10, 2016 Category: Cancer & Oncology Source Type: research

Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer
Abstract Despite recent improvements, triple-negative breast cancer (TNBC) remains a breast cancer subtype with poor prognosis. TP53 mutations are commonly associated with TNBC, suggesting a role in breast cancer carcinogenesis. In addition to mutations, several reports focused on TP53 polymorphisms and their association with breast cancer risk and outcome. TP53 codon Pro72Arg polymorphism may predict response to anti-cancer therapy as Pro72 is apparently less effective in the induction of apoptosis. Here, we investigated a potential association of TP53 mutations with TP53 codon 72 polymorphism and clinic...
Source: Memo - Magazine of European Medical Oncology - May 9, 2016 Category: Cancer & Oncology Source Type: research

Intravascular large B‑cell lymphoma
We present a case who could be treated successfully with chemotherapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 3, 2016 Category: Cancer & Oncology Source Type: research

Congress Report ESMO Asia 2015
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 8, 2016 Category: Cancer & Oncology Source Type: research